Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of rifampicin on steady-state pharmacokinetics of balovaptan in healthy volunteers
NL-OMON46088Active, not recruiting
- Sponsor
- Roche
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of balovaptan and rifampicin in Autism Spectrum Disorder (ASD), sponsored by Roche. Primary endpoint: Effect of multiple doses of rifampicin on balovaptan pharmacokinetics. Started Jul 2018; status: active, not recruiting.
02
Drugs
balovaptanrifampicin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NL-OMON46088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46088.